{
  "kind": "treatment",
  "slug": "acamprosate-campral",
  "type": "addiction-treatment",
  "name": "Acamprosate (Campral)",
  "summary": "A medication used to help maintain abstinence in individuals with alcohol use disorder.",
  "description": "Acamprosate is a synthetic amino acid derivative that modulates glutamatergic neurotransmission. It is approved for the maintenance of abstinence in patients with alcohol dependence who have achieved sobriety. It is most effective when combined with counseling and psychosocial support.",
  "category": "medications/addiction-treatment",
  "tags": [
    "alcohol-use-disorder",
    "relapse-prevention",
    "glutamate-modulator"
  ],
  "metadata": {
    "drug_classes": [
      "Glutamate Modulator",
      "Anti-craving Agent"
    ],
    "therapeutic_categories": [
      "Alcohol Use Disorder",
      "Addiction Medicine"
    ],
    "mechanism_categories": [
      "Other"
    ],
    "administration_routes": [
      "Oral"
    ],
    "prescription_status": "Prescription Required",
    "controlled_substance": false,
    "generic_available": true,
    "brand_names": [
      "Campral"
    ],
    "dea_schedule": null,
    "fda_pregnancy_category": "C",
    "age_groups": [
      "Adult",
      "Geriatric"
    ],
    "treatment_duration": [
      "Long-term"
    ],
    "specialty_areas": [
      "Addiction Medicine",
      "Psychiatry",
      "Primary Care"
    ],
    "fda_approval_year": 2004
  },
  "clinical_metadata": {
    "primary_indications": [
      "Substance Use"
    ],
    "off_label_uses": [
      "Craving reduction in other substance use disorders (limited evidence)"
    ],
    "contraindications": [
      "Severe renal impairment (CrCl ≤ 30 mL/min)",
      "Known hypersensitivity to acamprosate or excipients"
    ],
    "monitoring_required": [
      "Renal function"
    ],
    "efficacy_rating": {
      "alcohol-relapse-prevention": 4,
      "overall_tolerability": 4
    }
  },
  "search_metadata": {
    "searchable_terms": [
      "acamprosate",
      "campral",
      "alcohol dependence",
      "relapse prevention"
    ],
    "synonyms": [
      "calcium acetylhomotaurinate"
    ],
    "common_misspellings": [
      "acamprosate",
      "campril",
      "camprilal"
    ]
  },
  "sections": [
    {
      "type": "indications",
      "items": [
        "Maintenance of abstinence in alcohol use disorder after detoxification"
      ]
    },
    {
      "type": "mechanism",
      "text": "Believed to restore the balance between excitatory (glutamate) and inhibitory (GABA) neurotransmission in the brain disrupted by chronic alcohol exposure."
    },
    {
      "type": "dosing",
      "adult": {
        "start": "666 mg three times daily",
        "adjustment": "For moderate renal impairment (CrCl 30–50 mL/min): 333 mg three times daily",
        "max": "1998 mg/day"
      },
      "geriatric": "Same as adult; adjust for renal function",
      "hepatic_impairment": "No adjustment needed",
      "renal_impairment": "Avoid if CrCl ≤ 30 mL/min"
    },
    {
      "type": "dosage_forms",
      "items": [
        "Enteric-coated tablets: 333 mg"
      ]
    },
    {
      "type": "onset_duration",
      "text": "Therapeutic effect typically begins within 5–8 days of initiation; benefits maintained with ongoing therapy."
    },
    {
      "type": "adverse_effects",
      "common": [
        "diarrhea",
        "flatulence",
        "nausea",
        "itching",
        "dizziness",
        "insomnia"
      ],
      "less_common": [
        "anxiety",
        "depression",
        "dry mouth",
        "paresthesia"
      ],
      "serious": [
        "suicidal ideation",
        "severe allergic reaction"
      ]
    },
    {
      "type": "warnings",
      "black_box": null,
      "other": [
        "Monitor mood; may increase risk of depression or suicidal ideation",
        "Ineffective for patients who have not stopped drinking before starting therapy"
      ]
    },
    {
      "type": "interactions",
      "items": [
        {
          "with": "Alcohol",
          "risk": "May reduce efficacy",
          "action": "Avoid alcohol consumption"
        },
        {
          "with": "No significant CYP interactions",
          "risk": "Minimal",
          "action": "No major precautions needed"
        }
      ]
    },
    {
      "type": "monitoring",
      "items": [
        "Renal function at baseline and periodically",
        "Adherence and alcohol use",
        "Mood and suicidality"
      ]
    },
    {
      "type": "special_populations",
      "pregnancy": "Use only if potential benefits justify potential risks.",
      "lactation": "Unknown excretion into breast milk; use with caution.",
      "pediatrics": "Not established; not recommended.",
      "geriatrics": "Dose adjustment based on renal function."
    },
    {
      "type": "tapering",
      "text": "No physiological withdrawal expected; can be discontinued without tapering."
    },
    {
      "type": "clinical_notes",
      "items": [
        "Most effective when initiated after detoxification and combined with psychosocial support.",
        "Does not prevent withdrawal symptoms; not indicated for acute detox.",
        "Primarily renally excreted; safe in hepatic impairment."
      ]
    },
    {
      "type": "references",
      "items": [
        {
          "label": "Prescribing Information",
          "url": "https://www.accessdata.fda.gov/"
        },
        {
          "label": "NIAAA Clinician's Guide",
          "url": "https://www.niaaa.nih.gov/"
        }
      ]
    }
  ],
  "seo": {
    "title": "Acamprosate (Campral): Dosing, Side Effects, Interactions",
    "description": "Evidence-based overview of acamprosate for alcohol use disorder, including dosing, efficacy, and safety."
  }
}
